18 October 2023 - NICE has published final evidence-based recommendations on the use of tofacitinib citrate (Xeljanz) for the treatment of patients with active ankylosing spondylitis.

Tofacitinib citrate is recommended as an option for the treatment of adults with active ankylosing spondylitis that is not controlled well enough with conventional therapy, only if:

• The use of a tumour necrosis factor (TNF) alfa antagonist is not suitable or do not control the condition well enough and
• Pfizer provides tofacitinib citrate according to the commercial arrangement

Read NICE technology appraisal guidance